Hoxton Ventures

Congrats to Ben Peters and the Cogna team on raising $15 million in Series A funding! Cogna solves high-impact business problems in vital industries like utilities, manufacturing, energy, and the public sector— which represent more than 70% of the economy. Its AI-powered platform enables non-technical teams to identify unique operational pain points within their operating models and generate tailored software solutions. Cogna provides a cost-effective alternative to traditional off-the-shelf software and unlocks value in a vast, underserved market adjacent to the $51 billion enterprise resource planning and $362.5 billion consultancy sectors. Read all about it on Sky News: https://lnkd.in/ec7pmtJg Or Techcrunch: https://lnkd.in/dxnNB3_p

Very excited to team up with Antler and Playfair to support emerging talent at the upcoming Junior VC Networking Drinks on 28th December!

Very pleased to see two Hoxton Ventures' portfolio companies recognized on this year's list of Bloomberg News' "Top 25 UK Startups to Watch for 2024." Congrats to CuspAI and Skin Analytics on their recognition. Both are making big strides in meaningful areas of impact with Cusp tackling climate change through discovery of sustainable materials and Skin Analytics using AI to identify malignant lesions with a smartphone while also relieving burden on the health system. We continue to believe in their joint missions and are inspired by their prospects ahead! https://lnkd.in/emtSZGVM

Congrats to the Kheiron Medical team on their acquisition by DeepHealth! We were early believers in the transformative ability of AI in the field of radiology and are pleased to see their mission to help breast cancer patients live longer, better lives through earlier detection continue. Their combined technology will not only drive better outcomes for patients, but can also help relieve radiologist shortages across the industry. Kudos to the leadership team of Peter Kecskemethy, Tobias Rijken and Sarah Justine Kerruish on their unwavering dedication to this important field. https://lnkd.in/eBUHafuX

Great piece offering insight into how Hoxton Ventures portfolio company Nomagic is helping bring the future of AI-enabled robotics to the warehouse operations and logistics of today. Current customers leveraging their technology include fashion retailer ASOS.com and logistics company FIEGE amongst others. We admire the founding team of Tristan d'Orgeval, Marek Cygan and Kacper Nowicki who continue to make progress against this difficult problem that can have a profound impact on the labor shortages within warehouses today while also improving safety and efficiency. https://lnkd.in/eweqebKR

Congrats to the Formance team announcing their new Formance Platform, a comprehensive suite of agnostic infrastructure services further extending their financial core system. This key milestone helps support their mission building and selling financial infrastructure to large enterprises and financial institutions. We're excited to see what they come up with next! https://lnkd.in/d62ywiN3

At Hoxton Ventures, our fund is premised on the idea that European founders would start and win the industry categories of tomorrow. Our latest investment, leading a $30 million seed round in CuspAI, alongside Basis Set and Lightspeed, exemplifies this. Co-founded by AI pioneer Max Welling and deep-tech commercialization expert Alyn Chad Edwards, CuspAI is leveraging generative AI, deep learning, and molecular simulation to completely change the material design process. Their platform acts like a search engine for materials, enabling the rapid generation and evaluation of novel structures with specific functionalities - and opens up huge opportunities for AI-designed materials to be used in carbon capture and storage, a critical technology for reducing greenhouse gas emissions. This industry alone is projected to be worth $4 trillion by 2050. It’s clear to us that AI has the ability to shake up how we design materials. CuspAI has assembled some of the best people in the world to do this, starting with both Chad and Max. They’ve also pulled in two of the leading figures in the AI industry, Geoffrey Hinton, sometimes described as the ‘Godfather of AI,’ who is joining Cusp’s advisory board, and Yann LeCun, Chief AI Scientist at Meta, and who posted on X about the company. Congratulations to the CuspAI team! https://lnkd.in/eq8ea_24

Great progress from the Ochre Bio team securing a multi-year data license agreement with GSK to further propel investigation into the drivers of liver disease. This partnership will allow Ochre Bio and GSK to build better AI models supporting more precise experiments to prioritise and accelerate development of medicines to address this critical condition. https://lnkd.in/eeETgHV6

Exciting news from the American Society For Mass Spectrometry (ASMS) who has announced that our portfolio company Inoviv has entered into a co-marketing agreement with Waters Corporation. This collaboration marks a significant step forward advancing targeted #proteomics and accelerating life-changing treatments. By combining their expertise, Inoviv aims to develop highly sensitive quantitative #biomarker assays using the unparalleled capabilities of Waters’ state-of-the-art Xevo TQ Absolute mass spectrometer. Stay tuned for more updates from Inoviv as they continue to drive innovation and make impactful strides in the field of proteomics - www.inoviv.com #ASMS2024

Congratulations to co-founders Jack O'Meara and Quin Wills and the whole team at Ochre Bio on securing a $1bn partnership deal with Boehringer Ingelheim to develop liver disease drugs. Liver disease is actually the 3rd largest cause of early in the UK which they are tackling head on. We are thrilled to see the progress they're making on the frontier of computational bio technology to combat this global disease. Read all about it in the Financial Times: https://lnkd.in/eSRPARNK